Connection

WILLEM OVERWIJK to Adjuvants, Immunologic

This is a "connection" page, showing publications WILLEM OVERWIJK has written about Adjuvants, Immunologic.
Connection Strength

0.455
  1. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006 May 01; 176(9):5213-22.
    View in: PubMed
    Score: 0.204
  2. Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. J Immunol. 2018 05 15; 200(10):3464-3474.
    View in: PubMed
    Score: 0.116
  3. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr Opin Immunol. 2017 Aug; 47:103-109.
    View in: PubMed
    Score: 0.111
  4. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 2009 May 26; 27(25-26):3484-8.
    View in: PubMed
    Score: 0.015
  5. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. J Interferon Cytokine Res. 2000 Jun; 20(6):589-96.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.